ZA895908B - Cytotoxic drug conjugates - Google Patents

Cytotoxic drug conjugates

Info

Publication number
ZA895908B
ZA895908B ZA895908A ZA895908A ZA895908B ZA 895908 B ZA895908 B ZA 895908B ZA 895908 A ZA895908 A ZA 895908A ZA 895908 A ZA895908 A ZA 895908A ZA 895908 B ZA895908 B ZA 895908B
Authority
ZA
South Africa
Prior art keywords
drug conjugates
cytotoxic drug
cytotoxic
conjugates
drug
Prior art date
Application number
ZA895908A
Other languages
English (en)
Inventor
George Joseph Cullinan
Joseph Cullinan George
Bennett Coleman Laguzza
Coleman Laguzza Bennett
William Leonard Scott
Leonard Scott William
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA895908B publication Critical patent/ZA895908B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA895908A 1988-08-08 1989-08-02 Cytotoxic drug conjugates ZA895908B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/230,084 US5006652A (en) 1988-08-08 1988-08-08 Intermediates for antibody-vinca drug conjugates

Publications (1)

Publication Number Publication Date
ZA895908B true ZA895908B (en) 1991-04-24

Family

ID=22863896

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA895908A ZA895908B (en) 1988-08-08 1989-08-02 Cytotoxic drug conjugates

Country Status (15)

Country Link
US (1) US5006652A (da)
EP (1) EP0354728A3 (da)
JP (1) JPH02131499A (da)
KR (1) KR900002804A (da)
CN (1) CN1040205A (da)
AR (1) AR245368A1 (da)
AU (1) AU619329B2 (da)
DK (1) DK382989A (da)
HU (1) HU206377B (da)
IL (1) IL91182A0 (da)
MX (1) MX164971B (da)
NZ (1) NZ230200A (da)
PH (1) PH27351A (da)
PT (1) PT91372A (da)
ZA (1) ZA895908B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
US5272253A (en) * 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
GR1001459B (el) * 1992-10-08 1993-12-30 Lilly Co Eli Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
ES2049656B1 (es) * 1992-10-08 1994-11-16 Lilly Co Eli Grupos de conjugados de farmacos con anticuerpos.
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
EP1355672A2 (en) 2000-12-01 2003-10-29 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use
DE60231868D1 (de) * 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
DE60326833D1 (de) * 2002-05-15 2009-05-07 Endocyte Inc Vitamin-mitomycin-konjugate
EP2529758A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US8044200B2 (en) * 2005-03-16 2011-10-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
KR101364912B1 (ko) * 2005-08-19 2014-02-21 엔도사이트, 인코포레이티드 복수-약제 리간드 공액체
WO2007022493A2 (en) * 2005-08-19 2007-02-22 Endocyte, Inc. Ligand conjugates of vinca alkaloids, analogs, and derivatives
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
NZ580132A (en) * 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
AU2008268432B2 (en) * 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
EP2209374B1 (en) * 2007-10-25 2014-12-03 Endocyte, Inc. Tubulysins and processes for preparing
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
CA2887727A1 (en) 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
JP6431038B2 (ja) 2013-03-15 2018-11-28 ザイムワークス インコーポレイティド 細胞毒性及び抗有糸分裂性化合物とその使用方法
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
HUE057768T2 (hu) 2014-09-17 2022-06-28 Zymeworks Inc Citotoxikus és antimitotikus vegyületek és azok alkalmazásának módszerei

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
FI820020L (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobulinkonjugater
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DK167884A (da) * 1983-03-30 1984-10-01 Lilly Industries Ltd Immunoglobulinkonjugater
EP0124502B1 (fr) * 1983-04-29 1991-06-12 OMNICHEM Société anonyme Nouveaux conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques contenant ces conjugués
LU86157A1 (fr) * 1985-11-12 1987-06-26 Omnichem Sa Nouveau procede de fabrication de conjugues de la vinblastine et de ses derives
US4675400A (en) * 1985-06-17 1987-06-23 Eli Lilly And Company Bifunctional derivatives of 4-desacetyl indole-dihydroindole alkaloids
EP0232693A3 (fr) * 1985-12-16 1988-04-06 La Region Wallonne Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
ZA873600B (en) * 1986-05-27 1988-12-28 Lilly Co Eli Immunoglobulin conjugates
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
FR2610198B1 (fr) * 1987-02-03 1990-06-15 Ire Celltarg Sa Conjugues d'hydrazide d'alcaloide de vinca lie a une immunoglobuline, procede de preparation et compositions pharmaceutiques en comprenant
IL89043A0 (en) * 1988-01-27 1989-08-15 Lilly Co Eli Antibody conjugates

Also Published As

Publication number Publication date
PH27351A (en) 1993-06-21
NZ230200A (en) 1991-11-26
KR900002804A (ko) 1990-03-23
IL91182A0 (en) 1990-03-19
JPH02131499A (ja) 1990-05-21
HUT50488A (en) 1990-02-28
MX164971B (es) 1992-10-09
EP0354728A3 (en) 1991-04-10
HU206377B (en) 1992-10-28
DK382989A (da) 1990-02-09
AU619329B2 (en) 1992-01-23
PT91372A (pt) 1990-03-08
AR245368A1 (es) 1994-01-31
EP0354728A2 (en) 1990-02-14
DK382989D0 (da) 1989-08-04
CN1040205A (zh) 1990-03-07
US5006652A (en) 1991-04-09
AU3933989A (en) 1990-02-08

Similar Documents

Publication Publication Date Title
IL91181A0 (en) Cytotoxic drug conjugates
IL91182A0 (en) Cytotoxic drug conjugates
ZA897437B (en) Pharmaceutical formulations
EP0335545A3 (en) Pharmaceutical formulations for parenteral use
GB9200417D0 (en) Cytotoxic drug therapy
ZA892315B (en) Pharmaceutical formulations for parenteral use
HUT53126A (en) Antibody medicament conjugates
GB2228922B (en) Packaging drugs
EP0299057A4 (en) INCREASING THE POWER OF CYTOTOXIC CONJUGATES.
EP0443027A4 (en) Drug composition
ZA899948B (en) Pharmaceutical preparation
IE892533L (en) Cytotoxic drug conjugates
IE892534L (en) Cytotoxic drug conjugates
ZA893463B (en) Drug adsorbates
GB8901158D0 (en) Administering drugs
IE883489L (en) Drug-monoclonalantibody conjugates
IL92583A0 (en) Tolerogenic immunoglobulin-protein conjugates
GB8813402D0 (en) Pharmaceutical formulations
GB8820273D0 (en) Pharmaceutical formulations
GB8810733D0 (en) Pharmaceutical formulations
GB8820175D0 (en) Pharmaceutical formulations
GB8820343D0 (en) Pharmaceutical formulations
GB8825297D0 (en) Pharmaceutical formulations
GB8820272D0 (en) Pharmaceutical formulations
GB8828994D0 (en) Pharmaceutical formulations